View all news

    Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer

    06/01/2025
    Download(opens in new window)PDF

    Multimedia Files:

    View all news
    Questions? Please contact us:
    1-800-950-5089 investor-relations@its.jnj.com